Last reviewed · How we verify

Propofol + Remifentanyl

Azienda Ospedaliera San Gerardo di Monza · Phase 3 active Small molecule

Propofol and remifentanil together provide rapid-onset sedation and analgesia by depressing the central nervous system through GABA potentiation and opioid receptor agonism, respectively.

Propofol and remifentanil together provide rapid-onset sedation and analgesia by depressing the central nervous system through GABA potentiation and opioid receptor agonism, respectively. Used for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care settings.

At a glance

Generic namePropofol + Remifentanyl
SponsorAzienda Ospedaliera San Gerardo di Monza
Drug classIntravenous anesthetic combination (hypnotic + opioid)
TargetGABA-A receptor (propofol); mu-opioid receptor (remifentanil)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Propofol is an intravenous hypnotic agent that enhances inhibitory GABA-A receptor signaling, producing sedation and unconsciousness. Remifentanil is a potent synthetic opioid agonist that binds mu-opioid receptors to provide rapid analgesia and anxiolysis. The combination is used for balanced anesthesia, allowing lower doses of each agent while achieving synergistic sedative and analgesic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results